Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
This study has been completed.
Information provided by:
Office of Rare Diseases (ORD)
First received: February 24, 2000
Last updated: June 23, 2005
Last verified: December 2001
I. Evaluate the long-term safety and tolerance of a synthetic formulation of dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have completed a prior GL701 protocol.
|Study Design:||Primary Purpose: Treatment|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Office of Rare Diseases (ORD):
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004665
Sponsors and Collaborators
|Study Chair:||Rosalind Ramsey-Goldman||Northwestern University|